NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Medical Technologies Advisory Committee (MTAC) meeting minutes

**Minutes:** Confirmed

**Date and time: 127th MTAC meeting - Friday 8th September 2023**

**Location:** Virtual meeting via Zoom

## Attendees

Committee members present

1. Jacob Brown (Chair) Present for all items
2. Kiran Bali Present for all items
3. Katherine Boylan Present for all items
4. Stacey Chang-Douglass Present for all items
5. Teik Goh Present for items 1-4.2

 (mid of part 2)

1. Neil Hawkins Present for all items
2. Avril McCarthy Present for all items
3. Abdullah Pandor Present for all items
4. Carl Roobottom Present for all items

NICE staff present

Anastasia Chalkidou, Associate Director Present for all items

Catherine Pank, Project Manager Present for all items

Izabela Syrek, Administrator Present for all items

Dionne Bowie, Health Technology Assessment Analyst Present for all items

Amy Crossley, Health Technology Assessment Advisor Present for all items

Bernice Dillon, Health Technology Assessment Advisor Present for all items

Evan Campbell, Health Technology Assessment Analyst Present for all items

Oye Afolabi, Health Technology Assessment Analyst Present for all items

Samantha Baskerville, Health Technology Assessment Analyst Present for all items

Peslie Ngambi, Health Technology Assessment Analyst Present for all items

Emma Gordon, Assistant Project Manager, Corporate Office team, Present for items 1-4.1

Emily Henderson, Content Designer – Guidance, Publishing team Present for all items

Edgar Masanga, Business Analyst, Resource Impact

Assessment team Present for all items

Rebecca Thomas, Scientific Adviser, Scientific Advice team Present for all items

Jade Stacey, Implementation Facilitator, Field Team Present for all items

Leonardo Koeser, Scientific Adviser, Scientific Advice team Present for all items

Michael Bell, Associate Health Technology Assessment Analyst,

Scientific Advice team Present for all items

Martin Njoroge, Senior Analyst, Data and Analytics Present for all items

Vandana Ayyar Gupta, Scientific Adviser, Data and Analyst Present for all items

Helen Crosbie, Public Involvement Adviser, Public Involvement

Programme Present for all items

Dr Meg Kiseleva, Information Specialist, CEDAR External

Assesment Group Present for all items

EAC representatives present

Ed Wilson, PenTAG Present for items 1-4.1

Max Barnish, PenTA Present for items 1-4.1

Specialist committee members present

Dr Robert Dudley (Lead), Consultant Clinical Psychologist,

Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust Present for all items

Dr Immanuel Rhema, Specialist Registrar (General Adult

Psychiatry) / NHS Clinical Entrepeneur, East London NHS

Foundation Trust Present for all items

Dr Elizabeth Murphy, Research Clinical Psychologist, Greater

Manchester Mental Health NHS Foundation Trust Present for all items

Lay Specialist Committee members present

Eva Roberts Present for all items

Thomas Kabir Present for all items

Professional experts present

Prof David Veale, Consultant Psychiatrist, Kings College London Present for items 1-4.1

Dr Alison Brabban, consultant clinical Psychologist; National

Clinical Advisor to AMH Programme, NHS England/Improvement;

Clinical Lead for Community Transformation, Tees, Esk & Wear

Valleys NHS Foundation Trust Present for items 1-4.1

Jemma Kehoe, Digital Mental Health, NHSE Present for items 1-4.1

## 1. Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from committee members: Donna Cowan, Michael Kolovetsios, Emily Lam, Karen McCutcheon, Naomi McVey, Huseyin Naci, Jai Patel, Kazem Rahimi, Roger Whittaker and Alun Williams.

## 2. News and announcements

* 1. n/a

## 3. Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 11th August 2023.

## 4. Evaluation of Early Value Assessment (EVA) of GID-HTE10016 Virtual reality for treating agoraphobia and agoraphobic avoidance: early value assessment

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external assessment group representatives, members of the public and company representatives from OxfordVR and XR Therapeutics.
		2. The chair asked all committee members, specialist committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* **Dr Liz Murphy** has declared a non-financial professional and personal interests as one of her current roles involves supervising the implementation of gameChange Virtual Reality therapy in her employing NHS Trust (0.2 FTE) funded internally by the Research & Innovation department of my employing NHS Trust.

She was the trial coordinator of the Manchester site of the NIHR funded clinical trial to evaluate gameChange Virtual Reality therapy and she is a co-author on the trial publication (Freeman et al., 2023; The Lancet Psychiatry).

Dr Murphy has also published a clear opinion about the value of gameChange Virtual Reality therapy for treating agoraphobic avoidance, specifically in psychosis. Her opinion has been published in local media (Manchester radio and Manchester TV news) and internal communications in my employing NHS Trust.

She had occasional meetings with Oxford VR to discuss the implementation project.

It was agreed that her declaration would not prevent Dr Mruphy from providing advice to the committee.

* **Professor Robert Dudley** has declared a financial interests as he works as a clinician in the NHS providing psychological therapies for people with psychosis. Hence he has an interest in seeing more access to helpful approaches being offered in the NHS.

He teaches for one day a year at Manchester on the CBT for Psychosis course. In this capacity he is paid for providing training in working with visual hallucinations. He also works at University of York as Professor of Mental Health two days a week and in that capacity teach on the topic of treatment of psychosis to undergraduate and masters students.

Prof Dudleyhas also declared a non-financial professional and personal interests as he was a co-applicant on the NIHR i4i funded trial on gameChange, which used virtual reality for people with psychosis. This paid for him for one day a week for around three years to run the trial, and he is a named co-author on the outcome paper, and a number of related publications (as evidenced on his CV). He has no stocks or shares or intellectual property or patent rights to the gameChange package.

He is working with Oxford VR as part of an ongoing service evaluation of the use of VR in a real world setting and in this context they have provided one VR headset (approx. cost £400), and access to the gameChange software for us to use in our evaluation. He no role with Oxford VR, hold no stock or shares, and have no paid consultancy or other role with them. He attended one meeting with them and lunch and tea and coffee was provided. (approx. £20). No payment for attendance, travel or accommodation was made.

Prof Dudley is a co-applicant on a grant with Professor Freeman who is one of the developers of Oxford VR and gameChange, and this is an NIHR funded trial of a treatment called Feeling Safer which uses web based platform to increase treatment for paranoia. This pays for 5% of my time and starts in April 2023. He is acting in a research/site lead capacity and have no stock or share options etc.

He is also a site lead on a trial called SLOWMO 2, Chief investigator is Dr. Amy Hardy at the Institute of Psychiatry, this starts next year and uses an app and related digital program to provide digital therapy to people with psychosis. He is costed for 10% of his time, and will recruit people into the study. He has no patent, or IP or stocks or shares related to this process. It is funded by Wellcome.

Prof Dudley is on the Trial Steering Committee for a study called AVATAR which investigates a new digitally delivered treatment for distressing hallucinations. He is not involved in the study beyond this monitoring role, and have no stocks, shares, IP or patents associated with this. The trial is funded by Wellcome. He receives no payment for this role. Meetings are virtual and no travel or accommodation costs have been incurred.

He is in discussion with XR therapeutics about applying for grant funding for a research project. Update from Sep 2023: He has submitted a grant application working with XR therapeutics to develop a new VR treatment for people with psychosis. They will find out in the Autumn if invited to stage two. He holds no stock or share options or IP or patents related to this proposed treatment.

He has received funding from the NIHR to be chief investigator on a study called MUSE FEP which investigated a new digitally delivered treatment for hallucinations for people with first episode psychosis. This funding paid for 15% of his time and finished last year. He holds no stock or share options or IP or patents related to this treatment.

Prof Dudley is also a co-applicant on a study called MUSE ARMS also funded by NIHR that uses the MUSE package described above with people at risk of transition to psychosis. This pays for his time 2.5%. As above there is no IP, patent, or stocks or shares associated with this research.

It was agreed that his declaration would not prevent Prof Dudley from providing advice to the committee.

* **Ms Eva Roberts** has declared a non-financial professional and personal interests as she is a member of Bipolar UK.

Ms Roberts also declared a financial interests as Project support officer – research and development. She used to work on gameChange as a peer support worker and administrative assistant in the Bristol site.

It was agreed that her declaration would not prevent Ms Roberts from providing advice to the committee.

* **Dr Thomas Kabir** has declared a non-financial professional and personal interests as he is co-applicant on the NIHR gameChange grant.

Dr Kabir has also declared an indirect interests as he is an active researcher in a PPI capacity on some research studies from the O-CAP research group at the University of Oxford. He has a visiting honorary appointment with the Department of Psychiatry at the University of Oxford.

Dr Kabir has declared an non-direct financial interest as his employer is due an IP payment from Oxford VR in relation to the gameChange VR therapy. This will go to his employer, the McPin Foundation rather than him personally. Update from Sep 2023: when employed by the McPin Foundation his organisation received at IP payment for gameChange from Oxford VR. The payment went wholly to his former employer. He is no longer employed by McPin.

Dr Kabir has also declared a financial interest as he is due to take up a new post with Prof Daniel Freeman at Oxford University in late August 2023.

It was agreed that his declaration would not prevent Dr Kabir from providing advice to the committee.

No other conflicts of interests were declared for this item.

* + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Robert Dudley.
	1. Part 2 – Closed session (professional experts, external assessment group representatives, company representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the draft Early Value Assessment. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the draft Early Value Assessment in line with their decisions.

## 5. Date of the next meeting

The next virtual meeting of the Medical Technologies Advisory Committee (MTAC) will be held on 22nd September 2023 and will start promptly at 09:00am.